Understand the source comparison
AOD-9604 / AOD9604: Research Applications Comparison
Lipolysis / Fat Mobilisation Studies Stimulates hormone-sensitive lipase in adipocytes; inhibits lipoprotein lipase to reduce triglyceride storage 250–500 mcg subcutaneous injection daily for 8–12 weeks in rodent models Human trials (Metabolic Pharmaceuticals
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Lipolysis / Fat Mobilisation Studies
- Stimulates hormone-sensitive lipase in adipocytes; inhibits lipoprotein lipase to reduce triglyceride storage
- 250–500 mcg subcutaneous injection daily for 8–12 weeks in rodent models
- Human trials (Metabolic Pharmaceuticals Phase 2b, 2007) showed no statistically significant weight loss vs placebo despite mechanistic promise
- Strong preclinical mechanistic data; human efficacy underwhelming. Best suited for mechanistic lipolysis research rather than weight-loss endpoints
- Cartilage Repair / Osteoarthritis Models
- Derived from hGH's C-terminus; may stimulate chondrocyte proliferation without systemic IGF-1 elevation
- Intra-articular injection 1–2 mg weekly in animal models; no established human dosing
- No published human clinical trials on cartilage outcomes; all evidence is preclinical or anecdotal
- Mechanistically plausible but entirely unproven in humans. Research-only compound
- Metabolic Research (Insulin-Independent)
- Does not bind hGH or IGF-1 receptors; preserves lipolytic effect without hyperglycaemic or mitogenic risk
- Same dosing as lipolysis studies; paired with glucose tolerance testing to confirm insulin neutrality
- The very feature that makes it 'safer' than hGH (no IGF-1 activation) also limits its anabolic potential
- Useful negative control in hGH studies; demonstrates that lipolysis can be uncoupled from growth pathways
- Injury Recovery (Soft Tissue)
- Hypothesised to support collagen synthesis and fibroblast activity via non-IGF-1 pathways
- 250–500 mcg daily subcutaneous; duration 4–8 weeks in soft tissue injury models
- All injury recovery claims are extrapolated from hGH data or anecdotal reports. No dedicated AOD-9604 injury trials exist
- High mechanistic speculation; no direct evidence yet. Better-studied peptides (BPC-157, TB-500) have stronger injury-repair datasets